Cliff Asness's FOLD Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 404,580 shares of Amicus Therapeutics, Inc. (FOLD) worth $3.19 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in FOLD, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 292,988 shares. Largest reduction occurred in Q1 2021, reducing 56,821 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +69,700 | New Buy | 69,700 | $5.95 |
| Q4 2014 | +2,700 | Add 3.87% | 72,400 | $8.31 |
| Q1 2015 | +17,800 | Add 24.59% | 90,200 | $10.88 |
| Q2 2015 | +18,124 | Add 20.09% | 108,324 | $14.15 |
| Q3 2015 | -19,107 | Reduce 17.64% | 89,217 | $13.99 |
| Q4 2015 | -41,163 | Reduce 46.14% | 48,054 | $9.70 |
| Q1 2016 | -27,899 | Reduce 58.06% | 20,155 | $8.43 |
| Q2 2016 | -20,155 | Sold Out | 0 | $0.00 |
| Q3 2017 | +193,922 | New Buy | 193,922 | $15.08 |
| Q4 2017 | +35,744 | Add 18.43% | 229,666 | $14.39 |
| Q1 2018 | +1,074 | Add 0.47% | 230,740 | $15.04 |
| Q2 2018 | -5,322 | Reduce 2.31% | 225,418 | $15.62 |
| Q3 2018 | -23,463 | Reduce 10.41% | 201,955 | $12.09 |
| Q4 2018 | -39,946 | Reduce 19.78% | 162,009 | $9.58 |
| Q1 2019 | +11,593 | Add 7.16% | 173,602 | $13.60 |
| Q3 2019 | -230 | Reduce 0.13% | 173,372 | $8.02 |
| Q4 2019 | -21,658 | Reduce 12.49% | 151,714 | $9.74 |
| Q1 2020 | -6,600 | Reduce 4.35% | 145,114 | $9.24 |
| Q2 2020 | -6,431 | Reduce 4.43% | 138,683 | $15.08 |
| Q3 2020 | -22,129 | Reduce 15.96% | 116,554 | $14.12 |
| Q4 2020 | +29,158 | Add 25.02% | 145,712 | $23.09 |
| Q1 2021 | -56,821 | Reduce 39.00% | 88,891 | $9.88 |
| Q2 2022 | -2,413 | Reduce 2.71% | 86,478 | $10.74 |
| Q3 2022 | +15,967 | Add 18.46% | 102,445 | $10.44 |
| Q4 2022 | +12,171 | Add 11.88% | 114,616 | $12.21 |
| Q1 2023 | +3,480 | Add 3.04% | 118,096 | $11.09 |
| Q2 2023 | +2,570 | Add 2.18% | 120,666 | $12.56 |
| Q3 2023 | -9,227 | Reduce 7.65% | 111,439 | $12.16 |
| Q4 2023 | -11,548 | Reduce 10.36% | 99,891 | $14.19 |
| Q1 2024 | -8,845 | Reduce 8.85% | 91,046 | $11.78 |
| Q2 2024 | -3,422 | Reduce 3.76% | 87,624 | $9.92 |
| Q3 2024 | +1,222 | Add 1.39% | 88,846 | $10.68 |
| Q4 2024 | +1,413 | Add 1.59% | 90,259 | $9.42 |
| Q1 2025 | -47,805 | Reduce 52.96% | 42,454 | $8.16 |
| Q2 2025 | +69,138 | Add 162.85% | 111,592 | $5.73 |
| Q3 2025 | +292,988 | Add 262.55% | 404,580 | $7.88 |
Cliff Asness's Amicus Therapeutics Investment FAQs
Cliff Asness first purchased Amicus Therapeutics, Inc. (FOLD) in Q3 2014, acquiring 69,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Amicus Therapeutics, Inc. (FOLD) for 41 quarters since Q3 2014.
Cliff Asness's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q3 2025, adding 404,580 shares worth $3.19 M.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 404,580 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $3.19 M.
As of the Q3 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Amicus Therapeutics, Inc. (FOLD) was 404,580 shares, as reported at the end of Q3 2025.